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ABSTRACT

Traumatic brain injury (TBI) induces a state of microglial activation, which includes
upregulation of macrophage functions and release inflammatory mediators such as certain
inflammatory cytokines. Current literature suggests that interleukin-1β is an important cytokine
mediator, which is dramatically increased after brain injury. Previous studies indicate that ATP is
released by traumatically injured astrocytes and serves as a cell-to-cell mediator through
purinergic receptors after in vitro injury. However, the mechanism of interleukin-1β release after
traumatic brain injury remains poorly defined and is difficult to study using in vivo models.
Using an in vitro model for traumatic brain injury (cell strain or stretch), we investigated the role
of the extracellular nucleotides (ATP) in regulation of interleukin-1β release in rat cortical brain
cells. We now report that activated microglia constitute the major source of interleukin-1β
release after in vitro trauma. ATP is a powerful stimulus for interleukin-1β release from
microglial cultures. Glutamate inhibits interleukin-1β release. ATP-induced interleukin-1β
release was blocked completely by the P2X7 receptor antagonist, oxidized ATP, and partially by
the P2X7 receptor antagonist suramin, suggesting that ATP stimulates interleukin-1β release
from microglia via purinergic receptor and the P2X7 receptor is responsible for the interleukin1β release. Blockage of interleukin-1β release by the purinergic receptor antagonists oATP and
suramin decreased cell damage in uninjured mixed organotypic brain cell culture exposed to
activated microglia. Taken together, these results suggest that interleukin-1β mediated
inflammatory events are regulated in activated microglia by extracellular nucleotides (ATP) via
purinergic receptors in central nervous system after in vitro trauma.
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INTRODUCTION

Traumatic Brain Injury (TBI)

Traumatic brain injury (TBI) is a major cause of death and disability (91). A traumatic
brain injury is an injury to the brain caused by an acceleration/deceleration injury to the head,
such as an automobile accident or being thrown from a bicycle, or a projectile injury such as with
a bullet, or a rapid movement injury such as in shaken baby syndrome. The injury can change
how the person acts, moves, and thinks. Even in very mild injuries, patients have problems with
cognition, including thinking, memory, and reasoning problems. In more serious cases of injury,
there are an estimated 52,000 individuals per year who die of TBI in U.S.A (138). It is a major
public health problem, especially among male adolescents and young adults.
TBI is believed to consist of two phases. A primary phase causes tissue damage at the
moment of insult by direct mechanical disruption, such as bruising and cuts. A secondary, or
delayed phase of damage, results in a sequence of extracellular and intracellular events leading
ultimately to loss of neuronal function, which are initiated at the time of insult but do not appear
clinically for hours or days after injury. Clinically, this is often presented as patients who regain
consciousness after head injury and demonstrate the ability to speak and obey commands, only to
die hours or days later (37). At present, the biochemical and cellular mechanisms that comprise
secondary injury are not entirely understood. However since secondary injury is delayed, it is
hypothesized that pharmacological intervention may be possible.
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The Pathophysiology of Traumatic Brain Injury (TBI)

After brain injury, microglia, the cells with immune functions in the central nervous
system, are rapidly activated in response to pathological stimuli and lead to various inflammatory
processes. Upon activation, microglia change their immunophenotype as well as the expression
pattern of inflammatory mediators including cytokines, chemokines, and neurotoxic substances
at the transcriptional level (133, 150). Activated microglia can exert both beneficial and harmful
actions on brain (73). Inflammatory mediators are involved in many actions of activated
microglia. Although transient activation is beneficial for defense processes by certain aspects of
the microglia immune response, such as phagocytosis of apoptotic or necrotic tissue and
secretion of neurotrophic factors, either chronic activation or overactivation may lead to or
exacerbate

neuronal

diseases

such

as

Alzheimer’s

disease,

ischemia,

and

human

immunodeficiency virus encephalitis (73).

Microglia are Key Modulators of Inflammation within the CNS

Microglia are recognized as the immune effector cells of the brain, or brain macrophages.
In normal brain, microglia exist in a resting or ramified state, in which inflammatory functions
and the macrophage immunophenotype are suppressed. For example, resting microglia do not
express common macrophage marker antigens on the cell surface, do not phagocytize or release
inflammatory mediators such as certain inflammatory cytokines and interleukins, and have a
2

decreased synthesis of hydrolytic enzymes (48, 51, 78, 97). Microglia are a major glial
component of the central nervous system (CNS), and play a critical role as resident
immunocompetent and phagocytic cells in the CNS (141), and serve as scavenger cells in the
event of infection, inflammation, trauma, ischemia, and neurodegeneration of the brain (136, 37,
41). The presence of activated microglia has been demonstrated in pathological lesions in several
neurological diseases including traumatic brain injury, neurodegenerative diseases (89),
autoimmune CNS diseases (14), and acquired immune deficiency syndrome dementia complex
(AIDS-DC) (50). Microglia were first described in 1932 by Rio-Hortega in silver-carbonatestained brain preparations at the light microscope level as a morphologically distinct cell type
with long and branched processes (116). Microglia have at various times been described as
mesodermal, monocytic, or ectodermal in origin (71, 128, 61, 6, 124), but the prevailing view is
that monocytes enter brain during embryonic development and differentiate into microglia
displaying many of the cell surface antigens found for macrophages.

So, microglia are

recognized as the immune effector cells of the brain, or brain macrophages.
Microglial cells are ubiquitous throughout the CNS and are well placed to sense changes
in the health of neurons and glia. They are positioned adjacent to neuronal cell bodies and are
interspersed among the oligodendrocytes and astrocytes of the white mater. In their resting or
ramified state, they have long, highly branched processes that extend into the parenchyma of the
CNS. (6). They do not express common macrophage marker antigens on the cell surface, do not
phagocytize or release inflammatory mediators such as certain inflammatory cytokines, and have
a decreased synthesis of hydrolytic enzymes (48, 51, 78, 97).In response to neuronal injury, such
as traumatic brain injury (TBI), ischemia, or bacteria invasion, they rapidly progress from their

3

resting ramified state to an activated state where they can proliferate, migrate, and increase de
novo express a number of immune-related molecules (46, 85, 131, 77). In the event of cell death,
they further differentiate into phagocytes (132). Microglia are key modulators of inflammation
within the CNS, which possess the ability to produce and release cytokines, chemokines,
interleukins, reactive oxygen and nitrogen species, and proteases. Microglia, particularly when
activated, possess numerous cytokine and chemokine receptors, which endow them with the
capacity to respond to cytokines released after insults to the CNS (10, 94). They also process and
present antigens (26, 7, 49, 8). As such, they play important roles in numerous neurological
diseases, including traumatic brain injury, multiple sclerosis, Alzheimer’s disease, and AIDS,
which have an inflammatory component. Many studies support the hypothesis that chronic or
abnormal activation of microglial cells exacerbates the cellular degeneration seen in these
diseases (54).

Astrocytes Release Soluble Factors Which Induce Microglial Activation

The other major type of glia in the CNS are astrocytes. Astrocytes maintain the
homeostatic environment of the CNS and play an important role in regulation of immune
responses by functioning as a source of proinflammatory cytokines, chemokines, and immune
effector molecules (113, 103). Astrocytic processes envelope neurons and form a glial limitans at
the subpial surface and around the vasculature. Imaging studies have shown that astrocytes are
interconnected by at least two distinct pathways: an intercellular pathway mediated by gap
4

junctions and an extracellular pathway mediated by P2 purinergic receptors that respond to
nucleotides such as ATP (58). Regulation of these properties of astrocytes in various disease
states may therefore represent an important component of the maintenance of appropriate
neuronal function. During neurogenesis, astrocytes assist in the correct migration of neurons to
their final destination, promote neurite outgrowth and direct growing neurites to their final target
in specific regions of developing brain (111, 139). In the adult, the anatomical proximity of
astrocytes to either neuronal synapses or to blood brain barrier makes these cells suited for
exerting a homeostatic control on the extracellular environment (99, 142, 88).
Astrocytes actively release a number of neurotransmitters and produce several
neurotrophins and pleiotrophins. Neurotransmitters affect astrocyte function as well as that of
surrounding neuronal cells, thus contributing to cell-to-cell signaling, whereas trophic factors
participate in the coordination of developmental processes and, in the adult, in the plasticity of
function in both neurons and astrocytes (88, 36).
Our laboratory has shown that soluble factors released by injured astrocytes induce
microglial activation, but we do not know how the “activation” occurs or precisely what the
soluble factors are. Previous studies showed that after brain injury, astrocytes release ATP (1),
which may induce microglial activation through stimulation of purinergic receptors on the
microglial plasma membrane. Extracellular purine nucleosides and nucleotides are ubiquitous
intercellular messengers, which affect cardiac function, platelet aggregation and vascular tone
(65, 107, 17, 24). In higher animals, adenosine triphosphate (ATP) behaves as neurotransmitters
or neuromodulators in the central nervous system (110, 28, 83, 129).
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Injured astrocytes release numerous of soluble factors which may induce microglial
activation, yet the mechanisms leading to microglial activation remain poorly defined. In
particular, few studies have established how interactions between soluble factors released by
injured astrocytes affect the innate immune response of microglia and provoked microglia to
become inflammatory.

ATP is a Major Signaling Molecule Mediating Intercellular Communication

ATP is a major factor mediating intercellular communication in the immune and
nervous systems and triggers a variety of strikingly different biological effects (38, 100,4, 19). In
the brain it is considered to be one of the dominant extracellular messenger for astrocyte-toastrocyte calcium-mediated communication. Astrocytes release ATP upon mechanical
stimulation (58) and respond to ATP with a propagating wave of intracellular calcium ([Ca2+]i)
(58 ), a process that is thought to serve as a long-range signaling system in the CNS (27, 108).
Increased release of ATP from astrocytes and neurons after injury may mediate some of the
pathology of TBI through purinergic receptors. (135). Functionally active purinergic receptors
have been detected in cultured and in situ microglial cells (69, 145, 104, 43, 143, 98), thus
suggesting the possibility that ATP may also act in astrocyte-to-microglia communication and
may be an intiating factor in the microglial inflammatory response.
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ATP Exerts Astrocyte-to-Microglia Communication via P2 Receptors Family

ATP is released from damaged cells as a result of ischemia or inflammation and serves as
a cell-to-cell mediator through cell surface P2 receptors, which are widely distributed throughout
the nervous system (66). Extracellular ATP is a ubiquitous signaling molecule that exerts its
diverse physiological effects through activation of P2 receptors. P2 receptor subfamilies have
been divided into two subtypes: P2X and P2Y. ATP exerts fast effects by directly gating cationconducting channels designated P2X receptors, which exist on a large variety of cells, including
many excitable cells and different leukocytes (106). Seven genes encoding P2X subunits (P2X1–
7) are known in mammals. All P2X subunits share a common membrane topology, with two
hydrophobic membrane-spanning segments (M1 and M2) separated by a large extracellular loop
of ∼300 amino acid residues, which comprise the ATP-binding domain. P2X receptors are
coupled to nonselective cation channels, allowing influx of Na +and Ca2+, leading to transient cell
depolarization, and currently seven subtypes (P2X1 – 7) are known (140, 19),whereas P2Y
receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14) are G-protein
coupled, and their activation leads to inositol lipid hydrolysis, intracellular Ca2+ mobilization, or
modulation of adenylate cyclase activation (105, 123). Microglia have been shown to express
multiple P2 receptor subtypes, including P2X7, P2Y2, and P2Y12 (104, 67), indicating that ATP
may be a critical regulator of microglial cell function. In fact, ATP strongly induces microglial
chemotaxis via the Gi- and Go-coupled P2Y12 receptor (63) by means of different types of P2
receptor and intracellular signals.
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P2X7 Receptor is the Only Pore-Forming P2X Family Member

In the P2 receptors family, P2X7 (formerly called P2Z) receptors are unique in several
respects compared to other P2X receptors (70, 101). In macrophages, ATP works via the P2X7
receptor, one of the most important members of the P2X family of nucleotide-gated channels that
are activated by extracellular ATP (102). P2X7 is a 595-amino acid polypeptide with two
membrane-spanning domains and intracellular N- and C-terminal domains (134, 114). The P2X7
receptor is the only pore-forming P2X family member, and its activation results in the opening of
a cationic channel with increased permeability to calcium and intracellular depolarization (38).
Like other members of the P2X family of ligand-gated ion channels, the P2X7 receptor forms a
nonselective channel in the presence of ATP (134, 114, 95, 15). However, unlike other members
of the family, the channel formed by the P2X7 receptor rapidly transitions to a pore-like structure
(95, 130, 147). Prolonged ligation of the P2X7 receptor commits the cell to death (33,109). By
activity, the P2X7 receptor is restricted to a limited number of cell types including monocytes,
macrophages, microglial cells, and some lymphocytes and cancer cells (33, 25). The
physiological function of this unusual receptor remains unclear.
The P2X7 receptor is inhibited by several compounds, including oxidized-ATP (149,
153), suramin, and PPADS (pyridoxal-phosphate-6-azophenyl-2-4-disulphonic acid) (114, 148,
23, 92). The antagonistic effects of these compounds are different among species and they also
vary among cell types even within the same species. Oxidized ATP (oATP) is a relatively
selective inhibitor of the P2X7/P2Z ATP receptor for extracellular ATP, which covalently
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modifies nucleotide- binding proteins, also can significantly attenuate proinflammatory signaling
(9).

IL-1β Level is Dramatically Increased after Brain Injury

Interleukin-1β (IL-1β) is one of the principal proinflammatory cytokines induced in the
brain as a result of systemic or local insult (64, 118). IL-1β is unique among cytokines, because
it is not secreted via the classical exocytic pathway. The lack of a secretory signal peptide
hampers its targeting to the endo-plasmic reticulum. Large amounts of IL-1β, synthesized as a
precursor polypeptide of 33 kD, are found in the cytosol, from which the cytokine gains access to
the extracellular medium. An additional step is required, because the propoly-peptide has to be
proteolitycally cleaved by the IL-1β converting enzyme (ICE or caspase I) (3, 79), to the mature,
fully active 17-kD form. ICE-mediated processing and the secretory step appear to occur
concomitantly and lead to the exclusive recovery of the mature form in the extracellular medium
(3, 79).
The cytokine interleukin-1β (IL-1β) has diverse actions in the brain. IL-1β mediates host
defense responses to local and systemic disease and injury (e.g. fever, slow-wave sleep, appetite
suppression and neuroendocrine responses) and to neuroinflammation and cell death in
neurodegenerative conditions, such as stroke and head injury (118). It has also been implicated in
chronic degenerative diseases, in particular, multiple sclerosis, Parkinson's and Alzheimer's
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diseases. Interleukin-1β has achieved master inflammatory cytokine status because of its ability
to initiate a wide variety of pro-inflammatory activities. For example, IL-1β can promote
expression of adhesion molecules on endothelial cells (11), cyclooxygenase 2 by mesangial cells
(57) and matrix degrading metalloproteinases by chondrocytes (45). As a result of these many
activities, IL-1β is implicated as a contributing factor to several human diseases including
rheumatoid arthritis (RA), osteoarthritis, and inflammatory bowel disease (31). However, on the
other hand, some studies show that repair of insult to the CNS has been increasingly attributed to
immune responses (32, 126, 146). Low level of IL-1β may activate cells within the CNS to
produce growth factors known to induce the proliferation and differentiation of oligodendrocyte
progenitors in vitro, which have survival-promoting activities on CNS neurons (5, 127, 52).
Therefore, low levels of IL-1β may be critical to brain function.
The mechanisms regulating the expression and action of IL-1β in the central nervous
system are poorly understood, but involve multiple effects on neuronal, glial and endothelial cell
function. Thus, the IL-1β system provides an attractive target for therapeutic intervention. (120).
Constitutive expression of interleukin-1β (IL-1β) is very low in the brain; however,
levels of IL-1β increase dramatically after injury, and IL-1β elevation is associated with many
neurodegenerative diseases (120). For instance, IL-1β is rapidly induced in experimental models
of stroke (96, 76), and mice that have decreased IL-1β production are significantly protected
from ischemic injury (47, 59, 125, 13). Similarly, administering IL-1 receptor (IL-1R) antagonist
or IL-1β blocking antibodies reduces neuronal death subsequent to ischemia (115, 151, 84).
There is also increased IL-1β production surrounding amyloid plaques in brains of patients with
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Alzheimer's disease and Down syndrome (56), and IL-1β has been implicated in the excessive
production and processing of β-amyloid precursor protein as well as the synthesis of most of the
known plaque-associated proteins (2). IL-1β also has been shown to be elevated in the spinal
fluid and within demyelinated lesions of patients with multiple sclerosis (MS) (62, 30, 90). It has
been also shown to be cytotoxic to mature oligodendrocytes in vitro (93, 21). Therefore, IL-1β
has been associated predominantly with exacerbating pathology in the CNS.
Three major pieces of evidence implicate IL-1β in acute neurodegeneration. [1]
Expression of IL-1β in rodents is increased rapidly in response to ischemic, hypoxic, excitotoxic
and traumatic insults, which all lead to neuronal loss (118). IL-1β is also elevated in human
neurodegenerative conditions (119). [2] Injection of IL-1β into the brains of rodents fails to
cause neuronal injury, but markedly exacerbates ischemic, excitotoxic or traumatic brain injury
(119). [3] Inhibition of IL-1β in vivo (by administration of either IL-1ra, a caspase inhibitor, IL1β antibody, or by deletion of the caspase 1 gene) dramatically reduces the neuronal loss in
rodents caused by focal or global and permanent or reversible cerebral ischemia, infusion of
excitotoxins (NMDA, kainate or AMPA) or mechanical injury (137, 119 ).
In peripheral blood monocytes, IL-1β release is induced by ATP. In macrophages, ATP
mediated IL-1β processing is due to activation of ICE or a related caspase (43, 34). ATP works
via the P2X7 receptor, the member of P2X family of nucleotide-gated channels that are activated
by extracellular ATP (102). In fact, ATP acts as an agonist of IL-1β post-translational processing
by binding to the P2X7 receptor and constitutes an efficient stimulus for promoting release of IL-
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1β (74, 44, 55). Therefore, release of IL-1β and purinergic receptor activation appear to be
critically linked.

A Model for Rapid Stretch-Induced Injury of Cells in Culture

In the recent studies of brain injury, a simple, reproducible in vitro model for examining
the morphologic, physiologic, and biochemical consequences of stretch-induced injury on tissuecultured cells of brain origin was developed (40). It is based on tissue strain or stretch. This in
vitro model simulates important components of in vivo traumatic injury, such as transient
changes in cell membrane permeability, release of intracellular lactate dehydrogenase (LDH),
influx of extracellular Ca2+ and a rise in [Ca2+]i , mitochondrial dilation and vacuolization. It
produces many of the effect reported in “in vivo” head injury and is a well-developed model (40).
Cells are grown in tissue culture wells having a deformable, 2mm thick silastic
membrane bottom. A cell injury controller was used to produce a closed system and exert a rapid
positive pressure of known amplitude (psi) and duration (msec). Stretch injury is produced by
delivering a reproducible 50 msec pressure pulse of air to the cells grown on the silastic
membrane. The deformation of the membrane is proportional to the amplitude and duration of
the air pressure pulse. Extent of cell injury was qualitatively assessed by light and electron
microscopy and quantitatively assessed by nuclear uptake of the fluorescent dye propidium
iodide (PrI), which is excluded from cells with intact membranes. Cell injury was found to be
proportional to the extent of the silastic membrane deformation (40). Increasing cell stretch
12

caused mitochondrial swelling and vacuolization as well as disruption of glial filaments.
Stretching also caused increased dye uptake, with maximum dye uptake occurring with a 50
msec pressure pulse duration, whereas deformations produced over longer periods of time
(seconds) caused little dye uptake. This model can be used to study the biochemistry and
physiology of injury as well as serve as a tool to examine the efficacy of therapeutic agents. In
many cases, an in vitro model allows investigation of many biochemical parameters not possible
with in vivo work.

Rationale and Objectives

Data supporting the dramatically release of IL-1β after brain injury is mounting. Many
studies suggest that ATP is released from damaged cells as a result of trauma and ischemia and
serves as a cell - to-cell mediator through cell surface P2 receptors. But, there is still considerable
skepticism regarding the mechanism of releasing and regulating of IL-1β after brain injury.
Therefore, consistent studies that accurately address the mechanism are urgently needed. In an
attempt to investigate the role of the extracellular nucleotides (ATP) regulating IL-1β signal
transduction in rats via a P2 receptor mediated pathway in central nervous system, the objectives
of this study were as follows: 1) to test which cell types in the CNS release IL-1β after in vitro
trauma (injured astrocytes or activated microglia. We didn’t test injured neurons because our
previous studies have shown that microglia are activated by medium from injured astrocytes). 2)
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to investigate if ATP released by injured astrocytes can regulate IL-1β release and increase the
level of IL-1β in the CNS after brain injury. 3) to block the effects of ATP, which induces
microglial activation via cell-to-cell signaling by using purinergic receptor antagonists. 4) to test
the effects of the increased level of IL-1β to the brain cells after injury (neurodegenerative or
neuroprotective). It is hoped that the outcome of this study will guide future endeavors toward
better understanding the mechanism of the extracellular nucleotides (ATP) released by injured
astrocytes regulating the IL-1β mediated inflammatory events via purinergic receptors in central
nervous system after in vitro trauma.
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MATERIALS AND METHODS

Materials

Pregnant Sprague–Dawley rats were obtained from Charles River Laboratories
(Wilmington, MA, U.S.A.). Dulbecco’s modified essential medium (DMEM), Dulbecco’s
phosphate-buffered saline (DPBS), Fetal bovine serum, Penicillin-Streptomysin, L-Glutamine,
horse serum, 0.25% Gibco trypsin and Fatty acid free albumin were obtained from Invitrogen
(Carlsbad, CA, U.S.A.). Adenosine 5’- triphosphate, L-glutamate acid, Suramin sodium salt,
Adenosine 5’- triphosphate periodate oxidized sodium salt (OATP), D-Glucose, and Propidium
iodide (PrI) were purchased from Sigma (St. Louis, MO, U.S.A.). Flex Plates and Hard Plates
were from Flexcell International (Hillsborough, NC, U.S.A.). Transwell were obtained from
Corning Incorporated (Corning, NY, U.S.A.). Interleukin-1β Rat Biotrak ELISA kits were
purchased from Amersham Biosciences (Piscataway, NJ, U.S.A.). The Orbital Shaker was
obtained from Bellco Glass (Vineland, NJ, U.S.A.).The commercially available model 94A Cell
Injury Controller was manufactured by the Biomedical Engineering Facility at Virginia
Commonwealth University (Richmond, VA, U.S.A.). Microplate reader and Auto strip washer
were purchased from Bio-Tek Instruments (Winooski, VT, U.S.A.).

15

Cell Culture
Astrocyte and Mixed Cell Dissection
Dissection

Mixed cultures of neuronal plus glial cells were initially prepared form 1–2-day-old
neonatal Sprague-Dawley rat pups. Pups were sacrificed by decapitation and the neocortices
were rapidly dissected in a sterile hood. First, the brains were removed and placed in a Petri dish
containing sterile dissecting saline (137 mM NaCl, 5.3 mM KCl, 0.17 mM Na2HPO4*7H2O, 0.22
mM KH2PO4, 10 mM HEPES, 33 mM Glucose). Cerebral hemispheres, olfactory bulbs,
hippocampal formations, basal ganglia and meninges were removed. The cleaned cortices were
removed and placed in a second Petri dish containing fresh dissecting saline. Care was taken to
avoid contamination of cortices by the olfactory bulb or lower brain stem.

Cell Preparation

The isolated cortices were moved to a 60mm dish with 5 ml dissecting saline containing
trypsin (0.25% in Hanks Gibco, fully sterilized) for 10 min. Cortical tissue was gently diced into
small pieces, and transferred to a tube containing 5 ml Astrocyte Feed medium, containing
Dulbecco’s modified essential medium (DMEM), 10% fetal bovine serum (FBS), PenicillinStreptomysin (prepared with 5,000 U/ml penicillin G sodium with 5,000 ug/ml streptomysin
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sulfate in 0.85% saline), and 2 mM L-glutamine. The tissue was washed by pipetting up and
down and the suspension was centrifuged for 5 min at 2,000xg to collect tissue and cells. The
supernatant was removed and 5 ml of culture medium was added for a second wash. After
washing, the supernatant was removed and 5 ml of culture medium was added and tissue
fragments were broken up by pipetting up and down with a 10 ml sterile pipet. The tissue
suspension was further dissociated by trituration with a series of flame – narrowed glass pipettes.
The suspension was then filtered with a 70-µm nylon cell strainer to remove undissociated tissue.
The filtrate, containing the suspended cells, was diluted with astrocytes media. Cell counts were
performed on a 10µl sample using a hemocytometer, and the cell suspension was adjusted to
contain 1.5x106 cells/ml. 1.5x106 cells were seeded into each well of a collagen coated Flex Plate
(the collagen- coated 25-mm- diameter Flex Plates have a 2-mm- thick Silastic bottom, with six
wells per plate). These plates then contained mixed organotypic brain cell cultures.
To prepare astrocytes and microglia, flask cultures were prepared. For the 150-cm2
tissue culture flasks, cells were seeded at an initial density of 8x106 cells per flasks.
All cell cultures were maintained in a 5% CO2 incubator at 37°C.

For the mixed

preparations cell culture, after 3 days, half of the medium was removed from each well and a
neuronal growth medium, Mixed Prep Feed medium (DMEM, 30% glucose, PenicillinStreptomysin, L-glutamine and 5% horse serum), was added. For the flask cultures, 15 ml
medium was removed from each 150-cm2 flasks and same amount of

growth medium,

Astrocyte Feed medium (DMEM, Penicillin-Streptomycin, L-glutamine and 10% FBS), was
added. Media was changed every 2 to 3 days after preparation. Mixed prep cells were used
between days 10 and 20 in vitro. Glial cells typically adhered to the membrane substrate, and the
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neuronal cells adhered to the glial cells. Neuronal processes and interconnections between the
various neuronal cell clusters were readily apparent.

Microglia Cell Culture

Flask cultures were used to subculture pure microglia.

After 7-10 days, flasks were

inspected for good health and the presence of microglia. (Microglia appeared as bright, rounded
cells, many of which are floating or are weakly attached).
Since microglia do not strongly adhere to the flask in these cultures, flasks were shaken
on an orbital shaker at room temperature for 1.5 hours at 210 rpm (on shaker setting 6). After
shaking, the flasks where sharply rapped on the bottom to remove any further microglia. The
medium, containing the microglia, was decanted into a sterile 50ml culture tube. Astrocytes,
neurons, and oligodendrocytes remain on the flask bottom. Flasks were washed once with 12 ml
of Astrocyte Feed medium (DMEM, Penicillin-Streptomycin, L-glutamine and 10% FBS), and
the wash was added to the 50 ml conicals. This wash contains additional microglia. Flasks were
kept for astrocyte cultures and 15 ml of Astrocyte Feed medium was added and flasks were
returned to the incubator.
For microglial isolation, the cell suspension was centrifuged at room temperature for 7
minutes at 1500xg. The supernatant was removed from the 50 ml tubes using gentle suction so
as not to disturb the pellet, which contains microglia.

Leaving about 5 ml of medium in the

tubes, the pellet was resuspended by pipetting up and down gently. If multiple 50 ml tubes were
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prepared, then all microglial suspensions were combined into one 50 ml tube. Cell counts were
performed on a 10 µl sample using a hemocytometer, and the cell suspension was adjusted to
contain 1.0x106 cells/ml. 1.0x106 cells were seeded into each well of a amino coated hard plate.
Amino coated hard plates will allow only microglia to grow and attach, since astrocytes and
neurons require different plate coatings. Control or resting microglia are cultured in either
Astrocyte Feed medium or astrocyte conditioned medium. Microglia cultured in Astrocyte Feed
medium (DMEM) generally will not divide, and appear to ramify. Note that the number of
microglia in a experiment was kept constant during cell preparation.

Trypsinization of Flasks for Astrocytes Culture

To prepare pure enriched astrocyte cultures, the flasks containing mixed organotypic
cultures are treated with trypsin (0.25% trypsin and 0.02% EDTA in saline), which detaches the
cells from the bottom of the flasks. In brain cell cultures, only the astrocytes and microglia
survive the trypsinization process. Since microglia have already been removed from these
cultures, preparation of pure astrocyte cultures is possible.
After 14 days cultivation, flasks from which microglia have been removed were used to
subculture pure astrocytes. The existing culture medium in flask was removed and flasks were
washed once with 12 ml plain DMEM (no calf serum, glutamine, pen/strep). 12ml fresh plain
DMEM was added and then flasks were incubated for 5 minutes. After incubation, for each
150cm2 flask, 10ml 0.25% trypsin in EDTA was added. Flasks were kept lying flat in the
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incubator at 37° C, for 2 minutes. After 2 minutes, the cells had not yet detached, but were
loosened from the flask. The trypsin solution was aspirated by vacuum. Then 12ml DMEM
without calf serum were added and flasks were incubated at 37° C for 10 minutes, sufficient time
to lift the cells from the flask bottom. Cells were detached from the flask bottom after 10 minutes
incubation. The flasks were sharply whacked on the bottom to help remove cells. The medium,
containing the astrocytes, was decanted into a sterile 50ml conical tube. Then the flasks were
rinsed with 12ml DMEM and the wash was added to the 50ml conical tubes (two flasks/tube).
The cell suspension was centrifuged at 1500xg for 7 minutes to pellet cells. The supernatant was
removed and 5ml of culture medium was added to resuspend and break up cell pellets by gently
pipetting up and down 10-20 times using a 5 or 10 ml pipette. Next, all astrocyte suspensions
were combined into 1 50 ml tube. Cell count was performed by a hemocytometer using a dilution
of 0.9 ml media to 0.1 ml cell suspension. The cell suspension was adjusted to contain 1.5x 106
cells/ml. 1.5x106 cells were seeded into each well of a collagen coated Flex Plate. Cell cultures
were maintained in a 5% CO2 incubator at 37°C.

Cells were confluent and ready for

experiments after 14 days cultivation.

Cell Injury

Confluent astrocytes were subjected to injury using a model 94A Cell Injury Controller
(Fig. 1). An inlet on the Cell Injury Controller is connected to a tank of compressed gas. The Cell
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Injury Controller regulates the pressure and duration of a pulse of air that is delivered through a
closed tube system to an adapter that fits with an airtight seal into the top of each tissue culture
well in the Flex Plate. A valve and timer (1-100 msec) on the Cell Injury Controller unit controls
the exact millisecond duration of the valve opening and the air pressure pulse. An external output
on the Cell Injury Controller allows recoding of the exact time and duration of the electrical
pulse on an oscilloscope.
The air pressure pulse can be delivered by pressing a trigger on the controller unit or
remotely by depressing a hand-held trigger attached to the Cell Injury Controller. The silastic
membrane of the Flex Plate well is rapidly and transiently deformed by a 50-ms pulse of
compressed gas, which deforms the 2-mm-thick flexible silastic membrane and adherent cells to
varying degrees controlled by pulse pressure. The extent of cell injury is dependent on the degree
of silastic membrane deformation or stretch (40). Based on the previous work, we have
arbitrarily defined a membrane deformation of 5.5mm as mild stretch, 6.5mm as moderate
stretch, and 7.5mm as severe stretch. These degrees of membrane deformation result in a biaxial
strain or stretch of 31, 38 and 54%, respectively (40). The cell injury model has been utilized in
numerous studies and has been shown that it replicates many of the features of injury that have
been decribed in vivo (40,122).
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Figure 1. Cell injury controller.
Cells grown to confluency on silastic-bottomed tissue culture wells are subjected to a controlled
amount of stretch by an air pressure pulse of controlled magnitude and duration. Variations in the
pressure pulse produce varying silastic membrane deformation and cell stretch.
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Propidium Iodide (PrI) Uptake

Injury was assessed by measuring uptake of propidium iodide (PrI). Propidium iodide
(PrI) is used as a detection method for live/dead cells. The dye is fluorescent orange with a
molecular weight of 792. Due to its size, it is normally excluded from cells with intact plasma
membranes. But when cells begin to die, their plasma membrane compromised and becomes
leaky. This allows Propidium iodide (PrI) to enter the cells, where it intercalates with DNA in the
nucleus, staining the nucleus a fluorescent red. So, dead or dying cells can be detected and
enumerated by PrI staining.
The culture media from the wells of the tissue culture plates used for experiments
were decanted and replaced with 1% FAF-DPBS (fatty acid free albumin-Dulbecco’s phosphate
buffered saline). Then 10 ul propidium iodide (1%) was added to each well. Cells were returned
to the incubator for 15 min after addition of propidium iodide (PrI). In order to focus using the
fluorescent microscope with water immersion lens, there needs to be a fluid level of 2.5 ml in
each tissue culture well. So, after the 15 minutes incubation, 1.5 ml of the 1% FAF-DPBS was
added to adjust the well volume to appropriate levels. Fluorescent stained nuclei were counted
using a Zeiss epifluorescence microscope. PrI-stained cells were quantified using a computerdriven imaging program (Felix 32 software). Ten fields (there is a 100 square grid in the
fluorescent microscope lens) were randomly counted within the grid. The count in 10 fields was
averaged to determine the count for that well. Total PrI cells were determined by multiplying
using a scaler.
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Interleukin-1β (IL-1β) ELISA Analysis

The rat interleukin-1β (IL-1β) ELISA is an enzyme-linked immunosorbent assay for the
quantitative measurement of rat IL-1β in cell culture supernatant. It provides a simple, specific
and precise quantitative determination of IL-1β in cell culture supernatants. The assay is based
on a solid phase ELISA, which utilizes an antibody for IL-1β bound to the wells of a microtitre
plate together with a biotinylated antibody to IL-1β and streptavidin conjugated to horseradish
peroxidase (Streptavidin-HRP). 96 well anti-rat IL-1β precoated stripwell microtitre plate (12
strips of 8 wells) is used in this ELISA assay. 50µl sample for each microtitre plate well was
collected from cell culture supernatants for IL-1β ELISA assay.

Reagent Preparation
Wash Buffer

A clean glass or plastic 2 liter container was used to prepare wash buffer. 30x wash
buffer may have a cloudy appearance. The entire contents of the 30x wash buffer was added to a
2 liter container and was diluted to a final volume of 1.5 liters with distilled or deionized water.
The solution was mixed thoroughly. Wash buffer was at room temperature prior to use in the
assay. If running partial plates, the reconstituted wash buffer was stored at 2-8°C.
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Preparation of Working Standards

Lyophilized standard was reconstituted and one vial per partial plate was used.
Standards were prepared shortly before use, and were used within the same day as reconstitution.
Standard was reconstituted by distilled or deionized water according to the reconstitution volume
stated on the standard vial label. The solution was mixed by gently inverting the vial until the
contents were completely dissolved. Then 7 tubes, one for each standard curve point: 2500,
1000, 400, 160, 64, 25.6 and 0 pg/ml were labeled. Serial dilutions for the standard curve were
prepared as follows: 1) Into the 2500 pg tube 250µl of sample diluent was added. 2) Into the
remaining tubes 240µl of sample diluent were added. 3) 250µl of the reconstituted standard was
added into the first tube, 2500pg/ml and mixed. 4) 160µl of this dilution was added into the next
tube, 1000pg/ml and mixed. 5) The standard curve was completed by repeating serial dilutions
four more times.

Streptavidin-HRP Solution

Streptavidin-HRP solution was prepared no more than 15 minutes prior to use by using a
15ml plastic tube. The streptavidin-HRP concentrate was centrifuged to force the entire contents
to the bottom of the tube. Then 30µl of streptavidin-HRP concentrate was added to 12ml
streptavidin-HRP dilution buffer and mixed gently. This is the streptavidin-HRP solution. To run
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a half plate, 15µl streptavidin-HRP concentrate was added to 6ml streptavidin-HRP dilution
buffer and mixed gently.

Assay Procedure
Sample and Biotinylated Antibody Reagent Incubation

The number of strips (12 strips on each microtitre plate, 8 sample wells on each strip)
required was determined and left these in the plate frame. The remaining unused strips was
placed back in the foil pouch with the desiccant provided and stored at 2-8°C, making sure the
foil pouch is tightly sealed. After running the assay, the plate frame was retained for the second
partial plate. When running the second partial plate, the reserved strips were securely placed in
the plate frame.
The locations of the rat IL-1β standards and test samples were recorded. Six standards
and one zero must be run in duplicate with each series of unknown samples. 50µl sample diluent
was added to each well. Then 50µl standard or sample was added to each well in duplicate. The
wells were mixed by gently tapping the plate several times. The plate was carefully covered with
an adhesive plate cover. Ensure that all edges and strips were sealed tightly by running a thumb
over the edges and down each strip. The plate was incubated for two hours at room temperature,
20-25°C. At the end of the incubation period, the adhesive plate cover was removed carefully.
The plate was washed three times with wash buffer, and 100µl of the biotinylated antibody
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reagent was added to all wells being used. Then the plate was carefully covered with an adhesive
plate cover and all edges and strips were tightly sealed by running a thumb over the edges and
down each strip. The plate was then incubated for 30 minutes at room temperature, 20–25°C. At
the end of the incubation period, the adhesive plate cover was removed carefully. The plate was
washed three times with wash buffer.

Washing the Plate

When washing the plate, the long sides of the plate frame was squeezed gently to ensure
that all strips remain securely in the frame. All wells were aspirated and washed three times with
wash buffer using auto strip washer. All wells should be filled with wash buffer. Then the plate
was bloted on paper towels or other absorbent material.

Streptavidin-HRP Solution Incubation

100µl of prepared streptavidin-HRP solution was added to each well. A new adhesive
plate cover was attached carefully, ensuring all edges and strips are tightly sealed. Then the plate
was incubated for 30 minutes at room temperature, 20-25°C. At the end of the incubation, the
adhesive plate cover was removed. The plate was decanted and then washed three times.
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Substrate Incubation and Stop Step

A new disposable reagent reservoir and pipette tips were used when adding the TMB
substrate solution and stop solution. Only the amount required for the number of strips being run
was dispensed from the bottle. 100µl of TMB substrate solution was added into each well.
Enzymatic color reaction was developed at room temperature for 30 minutes. The substrate
reaction yielded a blue solution that turns yellow when stop solution was added. After 30
minutes, the reaction was stopped by adding 100µl of stop solution to each well.

Reading the Absorbance

The absorbance should be measured on an microplate reader set at 450nm. The plate was
read within 30 minutes of stopping the reaction.

Calculation of Results

The standard curve is used to determine the amount of rat IL-1β in an unknown sample.
The standard curve was generated by plotting the average absorbance 450nm obtained for each
of the standard concentrations on the vertical (Y) axis versus the corresponding IL-1 β
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concentration on the horizontal (X) axis. A four parameter logistic curve fit was plotted using
curve-fitting software. The amount of IL-1β in each sample was determined by interpolating the
IL-1β concentration (X axis) from the absorbance value (Y axis).
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RESULTS

Injured Astrocytes do not Release IL-1β

Previous studies showed that astrocytes maintain the homeostatic environment of the
CNS and release soluble factors after brain injury. However the cytokine profile released by
astrocytes or microglia has been heavily debated. To test which cell type releases IL-1β in the
CNS after in vitro injury, we initially examined the injured astrocyte cultures. After two weeks
cultivation, confluent astrocyte cultures were subjected to injury using a model 94 A Cell Injury
Controller (figure 1). Based on our previous studies, we have arbitrarily defined three levels of
cell injury-mild, moderate, and severe- produced by deforming the silastic membrane on which
cells are grown by 5.5, 6.5, 7.5 mm respectively using 50-msec pulse of compressed air. These
degrees of membrane deformation result in a biaxial strain or stretch of 31, 38 and 54%,
respectively (40).

Cells were injured at mild, moderate and severe levels of injury. After

incubation times of 15 minutes, 3 hours, 6 hours, and 24 hours post-injury at 37 °C, medium was
collected from the injured astrocytes.

Controls consisted of uninjured astrocyte cultures,

incubated for similar time periods. IL-1β released into the medium was measured by ELISA as
descried in Materials and Methods.

As shown in figure 2, no IL- 1β was released by injured

astrocytes, suggesting that injured astrocytes are not the brain cell type that release IL-1β after
trauma.
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Figure 2. IL-1β release from injured astrocyte culture.
Astrocytes were subjected to mild, moderate and severe injury. Media were collected
at 15 minutes, 3 hours, 6 hours, 24 hours post-injury. Controls consisted of uninjured cells. IL-1β
released into the medium was measured as described in Materials and Methods.
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IL-1β is Released by Activated Microglia

Having noted no apparent release of IL-1β from injured astrocytes, we next examined
whether activated microglia release IL-1β after in vitro injury, because microglia are key
modulators of inflammation within CNS and possess the ability to produce different kinds of
soluble factors. Microglia are recognized as the immune effector cells of the brain. Presence of
activated microglia and their soluble products have been demonstrated in traumatic brain injury.
Using the in vitro model for traumatic injury, our previous studies showed that microglia
were not activated by direct stretch injury. Microglia were activated by exposure to medium
conditioned by injured astrocytes, and we have termed this indirect activation. In this experiment,
microglia were activated by exposure to medium conditioned by different levels injured
astrocytes.

Figure 3a shows IL-1β release by microglia cultured for 1 hour in medium

conditioned by exposure to mild, moderate, or severly injured astrocyte media respectively.
After incubation at 37° C for 1 hour, medium from actived microglia was collected for IL-1β
analysis. IL-1β released into the medium was measured by ELISA. As shown in figure 3b, a
significant release of IL-1β was observed. Controls consisted of microglia cultured in medium
conditioned by uninjured astrocytes, and showed no increased IL-1β release.
Figure 3b illustrates the IL-1β release by activated microglia (i.e., microglia culture in
medium conditioned by injured astrocytes).

The IL-1β level was detected from microglia

cultured in medium conditioned by mild, moderate, or severely injured astrocytes. Controls
consisted of microglia cultured in astrocytes-conditioned medium, and released low amount of
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IL-1β. As shown in figure 3b, culture of microglia with medium conditioned by injured
astrocytes increased IL-1β release in a manner dependent on the degree of injury. For example,
controls released 37 pg/ml IL-1β, while exposure to mild, moderate, and severely injured
astrocytes medium induced microglia to release 91 pg/ml, 136 pg/ml, and 269 pg/ml IL-1β. The
release of IL-1β from microglia gradually increases in a linear fashion throughout mild to severe
injury.
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Figure 3. IL-1β released from activated microglia.
(A) Microglia were cultured in medium conditioned by mild, moderate and severely injured
astrocytes at 37° for 1hour. Controls consisted of microglia cultured in astrocyte-conditioned
medium without injury. IL-1β released into the medium was measured by ELISA. Data are
mean±S.E. (bars) values of 3 separate experiments performed in duplicate. *P<0.05 versus
control. (B) The linear fashion of the IL-1β release from activated mcroglia throughout the mild,
moderate and severe injury spectrum. Data are mean±S.E. (bars) values of 3 separate
experiments performed in duplicate. *P<0.05 versus control.
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IL-1β Released by Activated Microglia after Different Incubation Periods

Consequently, additional experiments were conducted to examine the IL-1β release from
activated microglia. We observed the IL-1β release from activated microglia after different
incubation time periods, to examine the time course of IL-1β release during microglial activation.
In these experiments, microglia were cultured in medium conditioned by severely injured
astrocytes (cells were injured at 7.5mm stretch) and incubated at 37 °C for 1hour, 24 hours and
48 hours, respectively. Controls consisted of microglia cultured in uninjured astrocyte medium at
37 °C for 1hour, 24 hours and 48 hours, respectively. Media was collected after incubation and
IL-1β released into the medium was measured.
As shown in figure 4, the release of IL-1β from activated microglia gradually decreases
in a liner fashion throughout the 1 hour, 24 hours, and 48 hours incubation period. After 1 hour
incubation, the highest amount of IL-1β release was observed. Then with the incubation time
period increase, the level of IL-1β release gradually dropped. The precise mechanism of the
decrease of IL-1β release is currently unknown. It is possible that released IL-1β was gradually
degraded during the longer incubation time periods. Alternatively, the stimulus that provoked IL1β release by microglia may also have been degraded.
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Figure 4. IL-1β release from activated microglia after different incubation time period.
Microglia were cultured in medium conditioned by severely injured astrocytes for 1, 24, 48 hours.
Controls consisted of microglia cultured in astrocyte conditioned medium and incubated under
the same conditions. IL-1β released into the medium was measured by ELISA. Data are mean
±S.E. (bars) values of 3 separate experiments performed in duplicate. Note that some S.E. (bars)
are too small to show graphically. *P<0.05 versus control.
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ATP Induces IL-1β Release from Microglia

Our lab has previously shown that astrocytes and mixed organotypic brain cell cultures
release substantial amounts of ATP after in vitro injury. We therefore sought to determine
whether ATP may provoke microglia to release IL-1β. Following an extensive literature review,
we found that P2X7 ATP-gated channels are highly expressed in microglia. The P2X7 receptor
forms a nonselective channel in the presence of ATP. The channel formed by the P2X7 receptor
rapidly transitions to a pore-like structure that allows passage of large molecules. We therefore
asked if ATP acts as an agonist of IL-1β release by binding to the P2X7 receptors on the
microglial plasma membranes. To address this question, initially, we compared the level of IL1β release between microglia cultured in astrocyte-conditioned medium incubated for 1 hour
without ATP treatment and microglia cultured in astrocyte-conditioned medium with different
concentrations of ATP (0.01mM, 0.05mM, 0.1mM, 1mM). Note that with these experiments,
astrocytes were not injured.
Figure 5 shows the comparison of the IL-1β release between the microgolia cultured in
the astrocyte-conditioned medium alone and with varying concentrations of ATP.

The data

illustrates that after application of ATP, IL-1β release increased. Interestingly, we found that
lower concentrations of ATP (0.01mM, 0.05mM) significantly increase IL-1β release from
microglia, while addition of higher concentrations of ATP (0.1mM, 1mM) the IL-1β release was
not significantly different from controls.
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Figure 5. Effect of ATP on IL-1β release.
IL-1β was measured in microglia cultured in astrocyte-conditioned medium and incubated for 1
hour with the indicated concentrations of ATP. Controls consisted of microglial samples without
ATP treatment and incubated under the same conditions. Data are mean ±S.E. (bars) values of 3
separate experiments performed in duplicate. *P<0.05, ATP treatment significantly different
from non-ATP-treatment samples.
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1

ATP Induces IL-1β Release from Microglia after 24 hours Incubation

Subsequent experiments were conducted in which microglia were cultured in astrcocyteconditioned medium and incubated with ATP for 24 hours. Similarly, we found that application
of ATP induced IL-1β release from microglia during the longer incubation time period. In figure
6, ATP was added to microglia cultured in astrocyte-conditioned medium, and samples were
then incubated for an additional 24 hours. IL-1β released into the medium was measured by
ELISA. The concentrations of ATP used in this experiment were 0.01mM, 0.05mM, 0.1mM,
1mM.

Similar to previous results, ATP dramatically induced IL-1β release from microglia

cultured in astrocyte-conditioned medium after 24 hours incubation.

Again, at the higher

concentrations of ATP (0.1mM, 1mM) IL-1β release was not as high as when the lower
concentrations of ATP (0.01mM, 0.05mM) were used. For example, with 0.01mM and 0.05mM
ATP, IL-1β release was 120pg/ml and 88pg/ml respectively, whereas at higher concentrations of
ATP (0.1mM, 1mM), IL-1β release was only 47pg/ml and 36pg/ml respectively. As shown in
figure 6, when microglial samples were treated with 0.01mM, 0.05mM ATP, we observed a
significant difference in IL-1β release as compared to untreated controls. When cells were
treated with 0.1mM, 1mM ATP, no significant difference was detected between above two kinds
of microglia samples.
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Figure 6. Effect of ATP on IL-1β release after 24 hours incubation.
Microglia were cultured in astrocyte-conditioned medium and then incubated for 24 hours with
0.01mM, 0.05mM, 0.1mM, 1mM ATP. Controls consisted of microglial samples without ATP
treatment. IL-1β in the mediumwas measured by ELISA. Data are mean±S.E.(bars) values of 3
separate experiments performed in duplicate. *P<0.05, ATP treatment significantly different
from non-ATP-treatment samples.
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1

ATP Enhanced IL-1β Production via a Concentration-Dependant Manner

In summary, from the previous two experiments, we can see that two different kinds of
microglia samples were tested. One was microglia cultured in astrocyte-conditioned medium
with 0.01mM, 0.05mM, 0.1mM, 1mM ATP treatment and incubated for 1 hour. The other was
microglia cultured in astrocyte-conditioned medium with 0.01mM, 0.05mM, 0.1mM, 1mM ATP
treatment and incubated for 24 hours. As can be seen in figure 7, the effects of ATP on IL-1β
release are dose-dependent in both experiments. At the concentration of 0.01mM, ATP induced
the highest level of IL-1β release. When the ATP concentrations increased, the level of IL-1β
release gradually decreased in a linear fashion.
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Figure 7. ATP dose-dependently induces IL-1β release from microglia.
The yellow line represents microglia samples cultured in astrocyte-conditioned medium and
incubated for 1 hour after application of 0.01mM, 0.05mM, 0.1mM, 1mM ATP. The pink line
represents microglial samples cultured in astrocyte-conditioned medium and incubated for 24
hours following application of 0.01mM, 0.05mM, 0.1mM, 1mM ATP. IL-1β was measured in
the mediumby ELISA. Data are mean ± S.E. (bars) values of 3 separate experiments performed
in duplicate.
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1

Effects of Purinergic Receptor Antagonists on ATP-Induced IL-1β Release

Oxidized ATP (oATP) and suramin are relatively selective inhibitors of the P2X7
receptor for extracellular ATP.

We previously demonstrated that ATP treatment induced a

significant increase in IL-1β release from microglial cultures. We have previously shown that
astrocytes release ATP after in vitro trauma. The present results show that ATP induces IL-1β
release from microglia. Therefore, we hypothesized that administration of the purinergic receptor
antagonists oATP and surmain should block the release of IL-1β after injury. In figure 8,
microglia were pretreated with 300µM ATP and 1µM suramin for 30 minutes. Next, microglia
were cultured in medium conditioned by mild, moderate and severely injured astrocytes for an
additional 1hour. IL-1β released into the medium was measured by ELISA. Figure 8 illustrates
that pretreatment with oxidized ATP completely abolished the injury-induced release of IL-1β
from activated microglia. Pretreatment with suramin partially blocked the injury-induced IL-1β
release by 88% in microglia cultured in mild injured astrocyte medium and 86% in microglia
cultured in moderate injured astrocyte medium and 89% in microglia cultured in severe injured
astrocyte medium.

Therefore, there was a significant reduction in IL-1β production from

activated microglia by treatment with purinergic receptor antagonists. The data suggest that the
P2X7 receptor is responsible for IL-1β release since oATP completely blocks the P2X7 receptor
and suramin partially blocks the P2X7 receptor.
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Figure 8. Effects of purinergic receptor antagonists on ATP-stimulated release of IL-1β.
Microglia were pretreated with 300µM oATP and 1µM suramin for 30 minutes, then incubated
in medium conditioned by mild, moderate and severely injured astrocytes for an additional 1
hour. Controls consisted of activated microglia without treatment with purinergic receptor
antagonists. IL-1β released into the medium was analyzed by ELISA. Data are mean ± S.E.
(bars) values of 3 separate experiments performed in duplicate. Note that some S.E.(bars) are too
small to show graphically.*P<0.05, oATP and suramin treatment significantly different from no
treatment samples at same injury level.
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Glutamate Inhibits IL-1β Release from Microglia

Glutamate is a primary excitatory neurotransmitter in the CNS and is released by neurons
and astrocytes after traumatic brain injury, potentially causing excitotoxic damage. Microglia
have metabotropic glutamate receptors on the plasma membrane, suggesting the existence of a
glutamate-mediated signaling network between microglia and astrocytes. Since high extracellular
glutamate is a signal for neuronal demise, we reasoned that excitotoxic concentrations of
glutamate should also stimulate IL-1β release. In our studies, surprisingly, it was discovered that
after application of glutamate to microglia, the release of IL-1β from microglial culture
decreased. As shown in figure 9, we compared the level of IL-1β release between microglia
cultured in astrocyte-conditioned medium for 1 hour without glutamate treatment and microglia
cultured in astrocyte-conditioned medium with different concentration of glutamate (0.1µM,
1µM, 10µM, 100µM) treatment. Figure 9 illustrates the comparison of the IL-1β release from
microglial samples without glutamate treatment versus microglia samples with glutamate
treatment. As shown in figure 9, a significant reduction of IL-1β release was observed from the
microglial samples with glutamate treatment. For example, when microglia were treated with
0.1µM glutamate, IL-1β was decreased by 64%.
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Figure 9. Effect of Glutamate on IL-1β release.
Microglia were cultured in astrocyte-conditioned medium with 0.1µM, 1µM, 10µM, 100µM
glutamate, respectively, then incubated for additional 1 hour. IL-1β release was measured in the
medium. Controls consisted of microglia without glutamate treatment. Data are mean ±S.E.
(bars) values of 3 separate experiments performed in duplicate. *P<0.05 versus control.
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Glutamate Decreases IL-1β Release from Microglia after 24 hours Incubation

We reasoned that perhaps a longer exposure to glutamate was required to initiate IL-1β
release. Therefore, subsequent experiments were conducted in which microglia were cultured in
astrocyte-conditioned medium with or without different concentrations of glutamate for 24 hours.
The IL-1β level was measured after 24 hours incubation. Similarly, we observed that application
of glutamate (0.1µM, 1µM, 10µM, 100µM, respectively) decreased IL-1β release from microglia.
Figure 10 shows that different concentrations of glutamate (0.1µM, 1µM, 10µM, 100µM) were
added to microglia cultured in astrocyte-conditioned medium and samples were then incubated
for 24 hours. IL-1β level in the medium was measured by ELISA. Controls consisted of
microglia samples without glutamate treatment. Data illustrate that all concentrations of
glutamate decrease IL-1β release from microglia samples after 24 hours incubation. Interestingly,
with lower concentrations of glutamate (0.1µM, 1µM) treatment, a significant reduction of IL-1β
level was observed in this experiment. These data suggest that lower concentrations of glutamate
(0.1µM, 1µM) decrease IL-1β release dramatically.

56

Figure 10. Effects of glutamate on IL-1β release from microglia after 24 hours incubation.
Microglia were cultured in astrocyte-conditioned medium with or without glutamate and
incubated for 24 hours. Controls consisted of microglia samples without glutamate treatment. IL1β released into the medium was observed after glutamate application. Data are mean ±S.E. (bars)
values of 3 separate experiments performed in duplicate. Note that one S.E.(bar) is too small to
show graphically.*P<0.05 versus control.

57

IL-1ß (pg/ml)

35
30
25
20
15
10
5
0

Control
*
*
*

*

0.1

*

1

10

100

Glutamate concentration (µM)

58

Glutamate treatment

Effects of Glutamate on ATP-Stimulated Release of IL-1β

We demonstrated from above experiments that glutamate inhibits IL-1β release from
microglia cultured in astrocyte-conditioned medium, and our studies show that ATP induces IL1β release from microglia. We then investigated if glutamate has effects on ATP-stimulated IL1β release from microglia, since both glutamate and ATP are suspected to be released after
trauma.
As can be seen in figure 11, 0.1µM glutamate was added to microglia cultured in
astrocyte-conditioned medium and samples were incubated for 2 hours, then 0.01mM ATP was
added and samples were incubated at 37 °C for additional 1 hour and 24 hours, respectively. IL1β released into the medium was measured by ELISA. Controls consisted of microglia cultured
in astrocyte-conditioned medium with 0.01mM ATP treatment, but without glutamate treatment.
Figure 11 shows a significant reduction of IL-1β was observed in the microglia samples with
glutamate treatment. The result suggests that glutamate inhibits ATP-stimulated IL-1β release.
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Figure 11. Effect of glutamate on ATP-stimulated release of IL-1β.
Microglia were cultured in astrocyte-conditioned medium. Microglia were pretreated with
0.1µM glutamate for 2 hours. Next, 0.01mM ATP was added and samples were incubated for
additional 1 and 24 hours. Controls consisted of microglia treated with ATP, but without
glutamate. Data are mean ±S.E. (bars) values of 3 separate experiments performed in duplicate.
Note that one S.E.( bars) is too small to show graphically. *P<0.05 versus control.
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The Effects of Increased IL-1β on Uninjured Brain Cells

Many studies support the dramatic release of IL-1β after traumatic brain injury. The
results of our studies demonstrate that activated microglia are the source of IL-1β. Next, we
wanted to determine if microglial IL-1β was neurotoxic to organotypic brain cell cultures. In this
study, microglia were cultured on Transwells, which have a screened (12mm diameter, 0.4um
pore size) bottom. The screened bottoms retain the microglia while allowing soluble factors
produced by microglia to enter the culture medium. Our lab has previously shown that microglia
cultured on transwells and exposed to injured astrocytes cultures for 1 hour (i.e. activated), were
neurotoxic to uninjured cultured cultures. Here, we examine if exposure of microglia to
purinergic antagonists block the neurotoxicity associated with activated microglia. In figure 12,
prior to microglial activation, 300µM oATP and 1µM suramin were added to the microglial
cultures. Microglia were then co-cultured with severely injured astrocytes for 24 hours, to
activate the microglia. Microglia cultured on inserts were activated by exposure to medium from
injured astrocytes. The activated microglia were then transferred to fresh, uninjured mixed
organotypic brain cell cultures for an additional 24 hours. Previous studies from our lab have
shown that neuronal death occurs 24 hours after exposure to activated microglia. Therefore, we
examined cell death at this time period. Controls consisted of samples without purinergic
receptor antagonist treatment. Cell damage was assessed by measuring uptake of Propidium (PrI)
as described in Materials and Methods.
Figure 12 shows addition of 300µM oATP and 1µM suramin prior to microglial
activation, decreased cell damage in uninjured mixed organotypic brain cell cultures exposed to
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activated microglia. 300µM oATP significantly decreased cell damage in uninjured cell cultures
by 77%. 1µM suramin significantly decreased cell damage in uninjured cell cultures by 61%.
The results suggest that the ATP antagonists oATP and suramin block the ATP-stimulated IL-1β
release from activated microglia and decrease cell death after in vitro trauma.
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Figure 12. Effcets of ATP antagonists on cell death on uninjured cell culture.
Microglia samples were co-cultured with severely injured astrocytes for 24 hours. 300µM oATP
and 1µM suramin were added prior to microglial activation, then microglia were transferred to
uninjured mixed organotypic brain cell cultures and incubated for additional 24 hours. Controls
consisted of samples without purinergic receptor antagonist treatment. Cell damage was assessed
by measuring propidium iodide (PrI) uptake. Data are mean ±S.E. (bars) values of 3 separate
experiments. *P<0.05, oATP and suramin treatment significantly different from control samples.
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DISCUSSION

Significant advances have been made in our understanding of CNS trauma by the use of
in vivo animal models, which permit the study of the whole organism’s response to a multitude
of complex variables. However, in vivo models do not permit easy assessment of the effect of
trauma on individual cell types or on many biochemical pathways which are too difficult to study
in vivo. Further, the currently employed in vivo animal studies do not permit precise control of
the extracellular and intracellular events after trauma. Using a simple, reproducible and wellcharacterized in vitro model of traumatic injury, we have been able to gain new insights on the
biochemical and cellular mechanisms of brain cells following traumatic injury using this model.
Compare to the current in vivo models, using this in vitro model, we have the ability to
study the response of individual cell types to trauma or combine cell types to assess interactive
effects in a controlled environment. We have reproduced many of the post-traumatic effects
identified in vivo. Further, our in vitro model allows us to investigate biochemical pathways
which may difficult, if not impossible, to study in vivo. One of the other advantages of the in
vitro model is that one can rapidly injure a large number of cells. Also the cells in the various
areas of the membrane appear to be similarly injured.
The overall aim of this study was to investigate which brain cell type constitutes the
major source of IL-1β release after traumatic brain injury and how the release of IL-1β is
regulated. Many studies indicated that astrocytes maintain the homeostatic environment of the
CNS and play an important role in immune regulation, acting as a source of chemokines,
cytokines, and effector molecules that mediate inflammation (113, 103). Therefore, in this study,
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we initially examined injured astrocyte cultures. In contrast to some research, our data indicate
that injured astrocytes do not release IL-1β (figure 2) and activated microglia constitute the
major source of IL-1β release after traumatic injury. Conflicting results in various earlier studies
may be due to the use of impure astrocytes cultures, which can be readily contaminated with
microglia if care is not used in their removal.
Our previous studies showed that microglia were not activated by direct stretch injury.
Microglia were activated by exposure to medium conditioned by injured astrocytes, and we have
termed this “indirect activation”. Microglia were indirectly activated by exposure to medium
from injured astrocytes.
In our studies, we observed that in vitro trauma induced a pronounced release of IL-1β
from microglia activated by exposure to medium conditioned by injured astrocytes. Microglia
cultured in medium conditioned by uninjured astrocytes release only a small amount of IL-1β. In
contrast, when microglia were cultured in medium conditioned by injured astrocytes, the IL-1β
release increased dramatically (i.e. the IL-1β release from microglia cultured in severely injured
astrocytes medium is 7 folds higher than the IL-1β release from microglia cultured in uninjured
astrocyte medium) . Our results demonstrate that the release of IL-1β from activated microglia is
relatively dose-dependent on the degree of in vitro trauma delivered to the astrocytes from which
the conditioned medium is obtained (figure 3). To date, the mechanisms of IL-1β release in the
central nervous system are poorly understood. Our studies provided clear evidence that activated
microglia are the major source of IL-1β release after in vitro trauma.
Although microglial activation has been reported in response to ischemia, lesion,
autoimmune diseases and trauma, there have been relatively few studies which investigate the
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underlying causes of microglial activation and the consequences of activation on neuronal
recovery after injury. The processing of IL-1β and it’s secretion into the extracellular space are
key regulatory events in brain injury, yet also remain poorly understood. We know microglia
highly express the P2X7 receptor, which is a plasma membrane pore gated by extracellular ATP
(67). It is now well ascertained that ATP functions as an extracellular messenger in the nervous
system as well as in the gut, skin, cardiovascular apparatus, and immune system (18, 112, 35).
Previous studies established that extracellular ATP can promote processing of IL-1β from
monocytes and macrophages. (109). It is also known that astrocytes release ATP after traumatic
brain injury (1). Therefore, based on these previous studies, we hypothesized that ATP released
from injured astrocytes may induce microglial activation through stimulation of purinergic
receptors. Our data demonstrated that application of ATP to microglia cultured in astrocyteconditioned medium induces IL-1β release (figure 5). In the absence of ATP, the level of IL-1β
release from microglia is low. However, in the presence of ATP, the IL-1β release process was
dramatically enhanced. When 0.01mM, 0.05mM ATP were added, ATP triggered significant
release of extracellular IL-1β. These results suggest that ATP released by injured astrocytes may
constitute an early signal for microglial activation through stimulation of purinergic receptors on
the microglial plasma membrane. So, ATP is a critical regulator of microglial cell function.
Our findings provide strong evidence that ATP is an effective stimulus of IL-1β release
from microglia and this effect appears to be a microglia P2X7-mediated response. Many studies
show that the activation of P2X7 receptor results in the formation of a large transmembrane pore
(95,130, 147). Also, other studies show that in the peripheral immune system, ATP and its
metabolites also modulate the response of cells to inflammatory signals through interactions with
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P2 receptors. In human macrophages, ATP has been shown to provide a very important stimulus
required for the processing of IL-1β (43). These findings are consistent with our results
demonstrating that extracellular nucleotides trigger IL-1β release from microglia post trauma.
Various in vivo studies have demonstrated that after activation, microglia and their
soluble products are toxic to neurons, promoting secondary damage and bystander cell injury (7).
Therefore, we determined whether purinergic receptor antagonists block microglial activation
induced by exposure to medium conditioned by injured astrocytes. If specific purinergic receptor
antagonists are effective at decreasing microglial activation and release of IL-1β, we can
determine whether they also decrease neurotoxicity of microglia after injury. Inhibition of
microglial activation by purinergic receptor antagonists may then prove to be worthy of further
in vitro and in vivo investigation with respect to potential impact on pharmacological therapy for
traumatic brain injury. The purinergic receptor antagonists used in our experiments are oxidized
ATP (oATP) and suramin, which are relatively selective inhibitors of P2X7 receptors. Our data
shows that pretreatment with 300µM oATP and 1µM suramin significantly blocked the ATPinduced IL-1β release from activated microglia. Oxidized ATP completely abolished the ATPstimulated release of IL-1β and suramin partially blocked the IL-1β release. The results suggest
that the P2X7 receptor is responsible for IL-1β release since oATP completely blocks the P2X7
receptor and suramin partially blocks the P2X7 receptor. In other words, the binding of oATP
and suramin with receptors could competitively block the binding of extracellular ATP to the
same structures, thus limiting ATP-stimulated IL-1β release. Figure 8 shows that there was a
significantly reduction of IL-1β production from activated microglia with purinergic receptor
antagonists treatment, suggesting that blockade of P2X7 receptor signaling significantly
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downregulated ATP- induced IL-1β release. This supports our hypothesis that ATP released by
injured astrocytes stimulates IL-1β release from microglia via purinergic receptors.
Glutamate is a primary excitatory neurotransmitter in the CNS and is released by neurons
and astrocytes after traumatic brain injury, potentially causing excitotoxic damage (12).
Metabotropic glutamate receptors have been identified in microglia, however the function of
these receptors is unknown (22). Our lab has reported that metabotropic glutamate receptor
signaling is upregulated in microglia activated by exposure to medium conditioned by injured
astrocytes. Release of glutamate into the CSF occurs after traumatic brain injury in vivo (16, 53,
60) and glutamate is released from stretch injured neurons and astrocytes (16). Other groups
have shown that excessive release of glutamate or injection of excitotoxins into the brain
activates microglia (68, 80, 117). These results suggest the existence of a signaling loop between
glutamatergic neurons and microglia. However, to date, there have been no studies examining
the effects of glutamate signaling and IL-1β release in activated microglia. Surprisingly, in our
studies we observed that after application of glutamate to resting microglia, the release of IL-1β
decreased (figure 9). Similarly, as shown in figure10, a significant reduction of ATP-induced
IL-1β release were observed in the microglial samples treated with glutamate. The result further
proved the inhibitory effects of glutamate on IL-1β release from microglia. However, the precise
mechanism of inhibition is currently unknown. Our studies suggest a signaling networking
between the glutamate, ATP, and IL-1β release. To date, few studies have established how
interactions between soluble factors (like ATP, glutamate et.) released by injured astrocytes
affect microglial activation, so further studies need to be done to address this question in the
future.
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Our results provided clear evidence that glutamate inhibits IL-1β release. Current
literature suggests that IL-1β elevation is associated with many neurodegenerative diseases (120),
while low levels of IL-1β may activate cells within the CNS to produce growth factors known to
induce the proliferation and differentiation of oligodendrocytes progenitors, which have survivalpromoting activities on CNS neurons (5,127,52). So, from our studies, we can say that low
concentrations of glutamate may have some protective effects by inhibition IL-1β release after in
vitro trauma. However, there have been no studies on the inhibitory effects of glutamate on IL1β release. It is well know that administration of excitatory amino acid, such as glutamate, can
cause neuronal cell death and that this excitatory amino acid-induced neuronal cell death plays a
crucial role in the pathogenesis of neurodegenerative diseases (82, 39). So, a possible
explanation for the inhibitory effects of glutamate on IL-1β release is that glutamate causes
excitotoxic damage and cell death to microglial cell and the P2X7 receptor on the microglia
membrane may be damaged, so that the pore-forming structure of P2X7 cannot be formed even
though in the presence of ATP and then IL-1β release is inhibited. Many studies show that
glutamate has neurodegenerative effects in CNS (82, 39), while our studies suggest that
glutamate may have somewhat neuroprotetive effects by inhibition large amounts IL-1β release
after in vitro trauma. Alternatively, the presence of glutamate at certain concentrations may
promote anti-inflammatory properties in microglia, and may promote neuroprotective effects.
Although the concentrations of glutamate utilized in these experiments have been shown to be
excitotoxic to neurons in culture, we are examining microglia in these experiments.

The

concentrations used may be similar to the concentrations of glutamate which microglia sense at a
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“normal” synapse, thus initiating a signal in microglia that may indicate “normal” synaptic
transmission, ultimately resulting in a decrease in inflammatory properties.
Interleukin-1β (IL-1β) is the principal proinflammatory cytokine induced in the brain as a
result of systemic or local insult (64, 118). Interleukin-1β (IL-1β), originally described as an
immune cell mediator in the periphery, has been involved in the modulation of several
neurological functions (such as activate cells to produce growth factors, etc.) and dysfunctions
(64, 144). The mechanisms regulating the expression and action of IL-1β in the central nervous
system are poorly understood, but involve multiple effects on neuronal, glial and endothelial cell
function. Thus, the IL-1β system provides an attractive and intensely competitive target for
therapeutic intervention. (120). The cytokine IL-1β levels increase dramatically in a number of
different inflammatory and degenerative conditions, such as multiple sclerosis and Alzheimer’s
disease, with expression localized to activated microglia and macrophages (20). Many of the
stimuli which promote processing and release of IL-1β in macrophages also induce cell death
(109). Experiments both in vivo and in vitro have strongly implicated a role for this cytokine in
disease pathogenesis in many of these disorders (119). The neurodegenerative activities of IL-1β
are thought to be attributable to the induction of inflammatory mediators such as the cytokines
TNF α and IL-6, as well as toxic factors such as the free radical nitric oxide. In our studies, we
showed that the effects of IL-1β can be significantly downregulated by blockade of P2 receptors.
As shown in figure 12, microglia activated by severe injury, which release Il-1β, cause cell death
in uninjured cultures. Addition of 300µM oATP and 1µM suramin prior to microglial activation,
decrease cell damage in uninjured mixed cell cultures exposed to activated microglia. These
results suggest that the ATP-induced elevation in IL-1β may have the neurodegenerative effects
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and exacerbates the extent of tissue damage. Many studies show that IL-1β has been associated
predominantly with exacerbating pathology in the CNS. However, some studies demonstrated
that IL-1β appears to promote remyelination in the CNS. IL-1β may activate cells within the
CNS to produce growth factors known to induce the proliferation and differentiation of
oligodendrocyte progenitors in vitro (5, 127, 52). Taken together, these results suggest that low
level IL-1β may have somewhat protective effects, but high levels of IL-1β may increase the
severity of brain cell damage. In summary, as shown in figure 13, we have provided clear
evidence that the extracellular nucleotides (ATP) released by injured astrocytes regulate the IL1β mediated inflammatory events via purinergic receptors in central nervous system after in vitro
trauma. Given that the IL-1β released from activated microglia appear to have both
neuroprotective and neurodegenerative effects, we believe that our studies on the purinergic
antagonists may be manipulated to shift the balance from neurodegeneration to neuroprotection.
So, the inhibition of high level IL-1β expression, release, or actions may be of therapeutic value.
Further investigation into this dual role of IL-1β in cell injury may result in improved strategies
for treatment of TBI.
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Figure 13. Extracellular ATP regulates IL-1β release from microglial cells via P2X7 receptor
after in vitro trauma.
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